Immusoft is developing an approach to sustained delivery of protein therapeutics using a patient's own cells. The approach is called Immune System Programming (ISPTM). ISP entails collecting a type of the patient's immune cells, called B cells. In response to immune stimulation, B cells can turn into a biofactory state known as a plasma cell. Plasma cells manufacture and secrete thousands of antibodies per second. We harness this biofactory capability of the plasma cell by programming B cells to produce a given protein therapeutics.
Timeline
Funding rounds
SBA Awards
People
Cam Gallagher
Chief Business Officer
Jason Fontenot
Chief Scientific Officer
Monika Swietlicka
Vice President of Regulatory Affairs
Scott McIvor
Chief Development Officer
Sean Ainsworth
Chief Executive Officer
Further reading
Documentaries, videos and podcasts
Companies
References
Company attributes
Other attributes
Categories
Related Topics
Contributors
- 1
Dawson Sewell
Writing about startups. - 2
Erin Scherfner
loading information... - 3
Melanie Manipula
Helping organize knowledge. - 4
Amy Sar
Data entry, interested in artificial Intelligence and NLP. - 5
Reys Phillips
A graduate of Cleveland State University with a Bachelor of Science in Education. My main hobbies include story writing and reading. - 6
Chirag Jain
I am an engineer and a traveler. I love to explore new things around the world and I am on the way of it. I love to take challenges. Thanks! - 7
Dushyant Soni
Researcher